Dr. Brian Kadera's primary interest is understanding the underlying molecular signaling mechanisms that dictate recurrence and dedifferentiation of soft tissue sarcoma. The most common subtype, liposarcoma, exhibits a broad spectrum of clinical behavior as an indolent slow-growing tumor that changes little over decades and has a dedifferentiated histology with a greater than 80% recurrence rate and similar mortality. Little is known about the genetics that dictate this progression and usual chemotherapy is ineffective. Kadera is searching for novel targeted therapies and predictive biomarkers that indicate which tumors will recur and which will progress.
Toste PA, Nguyen AH, Kadera BE, Duong M, Wu N, Gawlas I, Tran LM, Bikhchandani M, Li L, Patel SG, Dawson DW, Donahue TR. Chemotherapy-Induced Inflammatory Gene Signature and Protumorigenic Phenotype in Pancreatic CAFs via Stress-Associated MAPK. Mol Cancer Res. 2016 May;14(5):437-47. doi: 10.1158/1541-7786.MCR-15-0348. Epub 2016 Mar 15.
Williams JL, Kadera BE, Nguyen AH, Muthusamy VR, Wainberg ZA, Hines OJ, Reber HA, Donahue TR. CA19-9 Normalization During Pre-operative Treatment Predicts Longer Survival for Patients with Locally Progressed Pancreatic Cancer. J Gastrointest Surg. 2016 Jul;20(7):1331-42. doi: 10.1007/s11605-016-3149-4. Epub 2016 Apr 25.
Toste PA, Li L, Kadera BE, Nguyen AH, Tran LM, Wu N, Madnick DL, Patel SG, Dawson DW, Donahue TR. p85-alpha is a microRNA target and affects chemosensitivity in pancreatic cancer. J Surg Res. 2015 Jun 15;196(2):285-293. doi: 10.1016/j.jss.2015.02.071. Epub 2015 Mar 6.
Kadera BE, Toste PA, Wu N, Li L, Nguyen AH, Dawson DW, Donahue TR. Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition. Clin Cancer Res. 2015 Jan 1;21(1):157-65. doi: 10.1158/1078-0432.CCR-14-0610. Epub 2014 Oct 27.